Literature DB >> 3903943

Mediterranean spotted fever: a cooperative study of 227 cases.

B Font-Creus, F Bella-Cueto, E Espejo-Arenas, R Vidal-Sanahuja, T Muñoz-Espin, M Nolla-Salas, A Casagran-Borrell, J Mercade-Cuesta, F Segura-Porta.   

Abstract

The clinical manifestations of 227 cases of Mediterranean spotted fever (Boutonneuse fever) were reviewed, and the epidemiologic aspects of 170 cases from the Vallés Occidental region in the county of Barcelona, Spain, were analyzed. In this area an increase in the incidence of the disease has been noticed during the last several years. The patients evaluated presented with high fever and a generalized maculopapular rash. The tache noire at the site of the tick bite was seen in 166 cases (73%). Other common clinical manifestations were myalgia (73%), headache (69%), conjunctivitis (32%), hepatomegaly (44%), and splenomegaly (19%). Hepatic function tests (serum glutamic-pyruvic transaminase, serum glutamic-oxaloacetic transaminase) gave abnormal results in 55% of all cases. The Weil-Felix reaction was positive in 79% of the cases; the OX19 strain of Proteus vulgaris was the strain most frequently agglutinated. Treatment with oral oxytetracycline or chloramphenicol was effective in all cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903943     DOI: 10.1093/clinids/7.5.635

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  31 in total

1.  Clinical and laboratory characteristics of 144 patients with mediterranean spotted fever.

Authors:  E Antón; B Font; T Muñoz; I Sanfeliu; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

2.  Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever.

Authors:  F Gudiol; R Pallares; J Carratala; F Bolao; J Ariza; G Rufi; P F Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Isolation and identification of Rickettsia massiliae from Rhipicephalus sanguineus ticks collected in Arizona.

Authors:  Marina E Eremeeva; Elizabeth A Bosserman; Linda J Demma; Maria L Zambrano; Dianna M Blau; Gregory A Dasch
Journal:  Appl Environ Microbiol       Date:  2006-08       Impact factor: 4.792

4.  Malignant boutonneuse fever and polymyalgia rheumatica: a coincidental association?

Authors:  G Chaumentin; T Zénone; C Bibollet; G A Denoyel; A Boibieux; F Biron; D Peyramond
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

5.  Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever.

Authors:  F Bella; B Font; S Uriz; T Muñoz; E Espejo; J Traveria; J A Serrano; F Segura
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Erythromycin versus tetracycline for treatment of Mediterranean spotted fever.

Authors:  T Muñoz-Espin; P López-Parés; E Espejo-Arenas; B Font-Creus; I Martinez-Vila; J Travería-Casanova; F Segura-Porta; F Bella-Cueto
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

7.  Ciprofloxacin therapy for Mediterranean spotted fever.

Authors:  D Raoult; H Gallais; P De Micco; P Casanova
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  Antibodies to Rickettsia conorii in dogs: seasonal differences.

Authors:  E Espejo; M D Alegre; B Font; A Font; F Segura; F Bella
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

9.  Host- and microbe-related risk factors for and pathophysiology of fatal Rickettsia conorii infection in Portuguese patients.

Authors:  Rita de Sousa; Ana França; Sónia Dória Nòbrega; Adelaide Belo; Mario Amaro; Tiago Abreu; José Poças; Paula Proença; José Vaz; Jorge Torgal; Fátima Bacellar; Nahed Ismail; David H Walker
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

10.  Human case of Rickettsia felis infection, Taiwan.

Authors:  Kun-Hsien Tsai; Hsiu-Ying Lu; Jih-Jin Tsai; Sheng-Kai Yu; Jyh-Hsiung Huang; Pei-Yun Shu
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.